Sanofi and Alnylam pact moves from research to delivery
The research phase of the RNAi therapeutics collaboration between Sanofi (Euronext: SAN) and Alnylam Pharmaceuticals (Nasdaq: ALNY) is over, the companies have announced.
In January 2018, the companies amended their agreement so that Sanofi would obtain global development and commercialization rights to the hemophilia candidate fitusiran, and pay Alnylam royalties on sales, while the US biotech would be in the box seat with Onpattro (patisiran) and follow-up hATTR amyloidosis therapy vutrisiran ALN-TTRsc02 and would pay royalties to the French drugmaker on sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze